Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Amkor Technology CFO Megan Faust Sells $35K of Stock
Megan Faust, CFO, sold 1,000 shares of Amkor Technology, Inc. at $35.00 a share, worth $35K in total on Nov 10, 2026. Shares held after the trade: 132,105 (-0.8%).
GAXOS.AI INC. reported a significant revenue increase to $7.08 million for the nine months ended September 30, 2026, compared to $0.69 million in the prior year, driven by a $1.75 million gain on the sale of gaming assets. Despite the revenue growth, the company incurred a net loss attributable to common shareholders of $2.86 million due to a substantial rise in selling, general, and administrative expenses.
David Buonasera, CTO, sold 871 shares of Magnite, Inc. at $29.00 a share, worth $25.3K in total on Nov 9, 2026. Shares held after the trade: 238,578 (-0.4%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.57M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $577.52 to $592.93 a share (average $586.32) in 14 transactions, worth $5.57M in total on Nov 10, 2026. Shares held after the trade: 324,443 (-0.0%).
Liquidmetal Technologies reported a net loss of $2.37 million for the nine months ended September 30, 2026, compared to $1.64 million in the prior year period. While product revenue increased slightly to $674 thousand, the company faced higher operating expenses and a $220 thousand loss on the disposal of property and equipment.
American National Group Inc. reported net income attributable to common stockholders of $939 million for the third quarter of 2026, a significant increase from $208 million in the prior year period. Total assets remained stable at $130.5 billion, while total equity decreased to $8.1 billion primarily due to a $2.2 billion unrealized investment loss recorded in other comprehensive income.
For the nine months ended September 30, 2026, Commonwealth Credit Partners BDC I, Inc. reported total investment income of $45.8 million and net investment income of $35.5 million, both down from the prior year period. Net asset value per share decreased to $866.13 from $895.75 at year-end 2025, primarily driven by $17.2 million in net unrealized losses on investments.
Brian Gephart, CFO, sold 3,700 shares of Magnite, Inc. at $28.78 a share, worth $106K in total on Nov 9, 2026. Shares held after the trade: 163,310 (-2.2%).
Advanced Drainage Systems M&A Deal with StormTrap Investments LLC
Advanced Drainage Systems, Inc. (ADS) has completed its acquisition of StormTrap Investments LLC from PSP Capital. The deal expands ADS's addressable market in highly engineered stormwater storage solutions and provides cross-selling opportunities within the water management industry.
Bain Capital Private Credit reported total investment income of $173.3 million for the nine months ended September 30, 2026, a significant increase from $88.3 million in the prior year period. Net investment income grew to $83.1 million as the company expanded its investment portfolio to $2.4 billion at fair value, up from $1.68 billion at the end of 2025.
AIM ImmunoTech reported a net loss of $9.95 million for the nine months ended September 30, 2026, compared to $9.78 million in the prior year. The company significantly strengthened its balance sheet through equity offerings and warrant exercises, increasing total assets to $9.75 million and achieving a positive stockholders' equity of $7.08 million.
SES AI Corp reported total current assets of $161.6 million as of September 30, 2026, a decrease from $216.3 million at year-end 2025, primarily driven by a reduction in short-term investments. The company continues to incur losses and highlights risks related to its drone cell manufacturing, AI-based services, and the integration of UZ Energy.
Industrial Logistics Properties Trust Insider Kevin C. Phelan Buys $12K of Stock
Kevin C. Phelan bought 2,000 shares of Industrial Logistics Properties Trust at $6.01 a share, worth $12K in total on Nov 9, 2026. Shares held after the trade: 9,500 (+26.7%).
Journey Medical Corp reported a 16.7% increase in total revenue to $53.4 million for the nine months ended September 30, 2026, compared to the prior year. The company significantly reduced its net loss from $10.2 million to $3.9 million over the same period, driven by improved operating margins and lower research and development expenses.
Target Corporation has elected Sally Grimes to its Board of Directors, effective December 1, 2026. Ms. Grimes, the former CEO of Diageo North America and Clif Bar & Company, will serve on the Audit & Risk and Infrastructure & Finance committees. Her appointment is intended to bring extensive consumer brand and innovation expertise to Target's long-term growth strategy.
William Twomey, Vice President and Chief Accounting Officer, has resigned from Xerox Holdings Corporation effective November 30, 2026, to pursue other opportunities. Chuck Butler, the company's current CFO, will serve as the interim principal accounting officer while a search for a permanent replacement is conducted.
Pono Capital Four, Inc. reported a net income of $1,571,816 for the period from inception (January 2, 2026) through September 30, 2026, primarily driven by $2,346,853 in income earned on marketable securities held in the Trust Account. As a shell company, it maintains $122,346,853 in its Trust Account while reporting a shareholders' deficit of $2,654,584 due to the redemption value of Class A ordinary shares.
Gemini Space Station reported Q3 2026 total revenue of $40.9 million, a 19% year-over-year decline driven by a 73% drop in platform spot trading volume. Despite the revenue decline, the company improved its net loss by 63% year-over-year to $58.6 million through a 30% reduction in operating expenses and lower headcount.
Term
Q3 2026
“Operating expenses declined for a third consecutive quarter, and as we invest in growth, we intend to stay disciplined about where those dollars go. We’re clear-eyed about the work ahead and committed to getting it right: deepening our relationships with the customers who use Gemini, continuing to iterate, and investing where customers and markets are headed. We expect to be judged on results, and we intend to earn the confidence of our customers and shareholders one quarter at a time.”
Tyler Winklevoss, CEO of Gemini
“We started Gemini in 2014 because we believed crypto would change how people save, spend and move value, and we’re in this for the long term. Gemini 2.0 is our bet that the platforms that last will be the ones that own the regulated infrastructure underneath. We’re building ours to serve customers directly and to be something other platforms can build on.”
Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.
Counterparty
Hebei Senlang Biotechnology Co., Ltd.
“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
Core Scientific Insider Todd M. Duchene Sells $125K of Stock
Todd M. Duchene sold 10,000 shares of Core Scientific, Inc. at $12.39 to $12.70 a share (average $12.45) in 2 transactions, worth $125K in total on Nov 9, 2026. Shares held after the trade: 1,113,286 (-0.2%).
enCore Energy Corp. is a non-accelerated filer and smaller reporting company focused on uranium exploration and extraction. As of November 9, 2026, the company had 195,668,102 common shares outstanding and reported a history of negative operating cash flows while pursuing an expansion-by-acquisition strategy.
Alexis Le-Quoc, CTO, sold 49,961 shares of Datadog, Inc. at $178.01 to $181.68 a share (average $179.52) in 5 transactions, worth $8.97M in total on Nov 9, 2026. Shares held after the trade: 438,072 (-0.0%).
Cibus, Inc. reported a net loss of $21.9 million for the third quarter of 2026, with revenue increasing to $0.8 million from $0.6 million in the prior year period. The company's cash position improved slightly to $10.7 million as of September 30, 2026, supported by $31.0 million in net cash provided by financing activities during the first nine months of the year.
Nakamoto Inc. entered into a second amendment to its Master Loan Agreement with Kraken to extend the maturity of 60 million USDT of its 165 million USDT outstanding principal from December 2026 to December 2027. The amendment also allows the company to include the net value of its Bitcoin derivatives positions as collateral, providing greater flexibility to manage Bitcoin price volatility. Following the update, the company has no scheduled principal payments due until June 2027.
Spero Therapeutics reported that the FDA approved GSK’s NDA resubmission for Utebzi in June 2026, shifting the company's focus to the development of SP001. As of November 6, 2026, the company had 58,264,577 shares of common stock outstanding and continues to rely on milestone payments and royalties from its GSK partnership to fund operations.
Magnite Insider Katie Seitz Evans Sells $758K of Stock
Katie Seitz Evans sold 26,178 shares of Magnite, Inc. at $28.96 a share, worth $758K in total on Nov 9, 2026. Shares held after the trade: 415,622 (-5.9%).
CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.
Term
Q3 2026
“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”
Johnny Wang, President and Chief Executive Officer
“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”
Johnny Wang, President and Chief Executive Officer
WhiteHawk Minerals Corp. reported Q3 2026 financial results including record production of 71.3 MMcfe/d and net income of $6.9 million. Concurrently, the company announced the $41.0 million acquisition of mineral and royalty interests in the Marcellus/Appalachian Basin from Three Rivers Royalty II, LLC. The company also declared a quarterly dividend of $0.50 per share.
Counterparty
Three Rivers Royalty II, LLC
“Continuing the momentum, WhiteHawk is benefiting from its base business and two-pronged acquisition strategy, driving an increase in Cash Available for Distribution and net asset value. We continue to benefit directly from our best-in-class operators’ performance and growth potential. We are particularly excited by EQT’s pending acquisition of Range, which brings together two of our largest Appalachia operators. We believe the combined company’s scale, inventory depth and low-cost structure are well aligned with WhiteHawk’s interests and further support the long-term development of our core mineral position. At the same time, our two-pronged acquisition strategy continues to deliver. Since our IPO, we have signed 22 acquisitions totaling $157.3 million, including 20 ground game transactions totaling over $11 million. We believe these transactions, and execution on our acquisition pipeline, will continue to drive meaningful value for shareholders in the short, medium and long term.”
Daniel Herz, Chairman, President and Chief Executive Officer
PepGen Inc. entered into an underwriting agreement to sell 25,000,000 shares of common stock at a public offering price of $5.00 per share. The company expects to raise approximately $125.0 million in gross proceeds (excluding the underwriters' 30-day option for an additional 3.75 million shares) to fund clinical development and general corporate purposes.